schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part
Company profile
Ticker
SDGR
Exchange
Website
CEO
Ramy Farid
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Schrödinger, LLC • Schrödinger GmbH • Synaptic Science LLC • Reo Discovery Limited • Faxian Therapeutics, LLC • Schrödinger Technologies Ltd • Schrödinger India Private Limited • Schrodinger Korea LLC • XTAL BioStructures, Inc. ...
IRS number
954284541
SDGR stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
11 Apr 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
S-3ASR
Automatic shelf registration
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
28 Feb 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Schrödinger Reports Third Quarter 2023 Financial Results
1 Nov 23
8-K/A
Schrödinger Reports Second Quarter 2023 Financial Results
3 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Schrödinger Reports Second Quarter 2023 Financial Results
2 Aug 23
Transcripts
SDGR
Earnings call transcript
2023 Q4
28 Feb 24
SDGR
Earnings call transcript
2023 Q3
1 Nov 23
SDGR
Earnings call transcript
2023 Q2
2 Aug 23
SDGR
Earnings call transcript
2023 Q1
4 May 23
SDGR
Earnings call transcript
2022 Q4
28 Feb 23
SDGR
Earnings call transcript
2022 Q3
4 Nov 22
SDGR
Earnings call transcript
2022 Q2
5 Aug 22
SDGR
Earnings call transcript
2022 Q1
5 May 22
SDGR
Earnings call transcript
2021 Q4
25 Feb 22
SDGR
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 255.61 mm | 255.61 mm | 255.61 mm | 255.61 mm | 255.61 mm | 255.61 mm |
Cash burn (monthly) | 11.80 mm | (no burn) | 21.64 mm | (no burn) | 16.65 mm | 10.37 mm |
Cash used (since last report) | 78.80 mm | n/a | 144.47 mm | n/a | 111.15 mm | 69.23 mm |
Cash remaining | 176.80 mm | n/a | 111.14 mm | n/a | 144.46 mm | 186.38 mm |
Runway (months of cash) | 15.0 | n/a | 5.1 | n/a | 8.7 | 18.0 |
Institutional ownership, Q3 2023
92.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 235 |
Opened positions | 43 |
Closed positions | 45 |
Increased positions | 75 |
Reduced positions | 79 |
13F shares | Current |
---|---|
Total value | 1.58 tn |
Total shares | 58.57 mm |
Total puts | 439.60 k |
Total calls | 567.80 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.43 mm | $238.25 bn |
Bill & Melinda Gates Foundation Trust | 6.98 mm | $197.37 bn |
Vanguard | 6.70 mm | $189.38 bn |
Baillie Gifford & Co | 2.95 mm | $83.41 bn |
ARK Investment Management | 2.84 mm | $80.17 bn |
Shaw David E | 2.40 mm | $0.00 |
STT State Street | 2.03 mm | $57.32 bn |
Credit Suisse | 2.00 mm | $56.52 bn |
FMR | 1.74 mm | $49.06 bn |
MS Morgan Stanley | 1.49 mm | $42.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Kenneth Patrick Lorton | Stock Option Common Stock | Grant | Acquire A | No | No | 27.51 | 30,000 | 825.30 k | 30,000 |
21 Mar 24 | Robert Lorne Abel | Stock Option Common Stock | Grant | Acquire A | No | No | 27.51 | 30,000 | 825.30 k | 30,000 |
6 Mar 24 | Kenneth Patrick Lorton | Common Stock | Option exercise | Acquire M | No | No | 4.34 | 5,574 | 24.19 k | 42,061 |
6 Mar 24 | Kenneth Patrick Lorton | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.34 | 5,574 | 24.19 k | 0 |
4 Mar 24 | Geoffrey Craig Porges | Common Stock | Sell | Dispose S | No | Yes | 26.353 | 3,315 | 87.36 k | 5,685 |
4 Mar 24 | Geoffrey Craig Porges | Common Stock | Grant | Acquire A | No | No | 0 | 9,000 | 0.00 | 9,000 |
4 Mar 24 | Geoffrey Craig Porges | Stock Option Common Stock | Grant | Acquire A | No | No | 25.24 | 90,000 | 2.27 mm | 90,000 |
4 Mar 24 | Ramy Farid | Stock Option Common Stock | Grant | Acquire A | No | No | 27.76 | 87,271 | 2.42 mm | 87,271 |
4 Mar 24 | Ramy Farid | Stock Option Common Stock | Grant | Acquire A | No | No | 25.24 | 126,000 | 3.18 mm | 126,000 |
News
10 Health Care Stocks Whale Activity In Today's Session
4 Mar 24
Citigroup Maintains Buy on Schrodinger, Lowers Price Target to $39
1 Mar 24
Critical Insights From Schrodinger Analyst Ratings: What You Need To Know
1 Mar 24
Goldman Sachs Maintains Neutral on Schrodinger, Lowers Price Target to $26
1 Mar 24
Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $33
29 Feb 24
Press releases
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
10 Apr 24
Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting
20 Mar 24
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
19 Mar 24
Qiming Venture Partners Becomes a UN PRI Signatory
25 Feb 24
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16 Feb 24